Publikationen für den 25. Kongress der EHA

Der diesjährige EHA-Kongress fand virtuell statt. Hier finden Sie eine Zusammenstellung der wichtigsten und interessantesten Präsentationen der deutschen Studiengruppen.

ALL

DOSE REDUCED CHEMOTHERAPY IN COMBINATION WITH BLINATUMOMAB FOR NEWLY DIAGNOSED OLDER PATIENTS WITH PH-NEGATIVE B-PRECURSOR ALL: FIRST RESULTS OF THE BOLD TRIAL
Nicola Gökbuget, Andrea Stoltefuß, Stefan Schwartz, Andreas Viardot, Lena Baumann, Monika Brüggemann, Christoph Faul, Maria Wachsmuth, Anne Wilke, Vladan Vucinic, Max Topp


AML

VALIDATION OF A GENE EXPRESSION BASED CLASSIFIER FOR THE PREDICTION OF RESISTANCE TO INDUCTION TREATMENT IN ACUTE MYELOID LEUKEMIA
Christian Moser, Vindi Jurinovic, Sabine Sagebiel-Kohler, Bianka Ksienzyk, Aarif Batcha, Nikola Konstandin, Annika Dufour, Stephanie Schneider, Maja Rothenberg-Thurley, Maria Cristina Sauerland, Dennis Görlich, Wolfgang Berdel, Utz Krug, Ulrich Mansmann, Wolfgang Hiddemann, Jan Braess, Karsten Spiekermann, Klaus Metzeler, Jörg Kumbrink, Tobias Herold

TRENDS IN FIRST-LINE THERAPY CHOICE IN PATIENTS ≥ 65 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA BETWEEN 2011 AND 2018: RESULTS FROM THE AMLCG REGISTRY
Andreas Rank, Isabel Sarger, Klaus H. Metzeler, Karsten Spiekermann, Jan Braess, Cristina Sauerland, Christoph Schmid, Wolfgang Hiddemann, Dennis Görlich

REMISSION AND SURVIVAL AFTER 90 MG VERSUS 60 MG DAUNORUBICIN IN 7+3 STANDARD INDUCTION FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS FROM THE RANDOMIZED CONTROLLED SAL-DAUNODOUBLE TRIAL
Christoph Röllig, Björn Steffen, Christoph Schliemann, Nael Alakel, Regina Herbst, Alwin Krämer, Stefan W Krause, Richard Noppeney, Zdenek Rácil, Kerstin Schäfer-Eckart, Andreas Neubauer, Claudia D Baldus, Martin Kaufmann, Jolana Mertová, Edgar Jost, Dirk Niemann, Jan Novák, Sebastian Scholl, Gerhard Held, Stefani Parmentier, Hubert Serve, Tomas Szotkowski, Pavel Zak, Carsten Müller-Tidow, Andreas Rank, Maxi Wass, Sebastian Buske, Michael Kramer, Frank Fiebig, Johannes Schetelig, Uwe Platzbecker, Christian Thiede, Wolfgang E Berdel, Gerhard Ehninger, Jiri Mayer, Martin Bornhäuser

OUTCOMES AND TREATMENT PATTERNS OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITHOUT TARGETED AGENTS: REAL-WORLD BENCHMARKS FOR FUTURE STUDIES FROM THE GERMAN SAL REGISTRY
Christoph Röllig, Michael Kramer, Christoph Schliemann, Alwin Krämer, Stefan W Krause, Mathias Hänel, Björn Steffen, Sabrina Kraus, Richard Noppeney, Martin Kaufmann, Kerstin Schäfer-Eckart, Lars Fransecky, Albrecht Reichle, Andreas Neubauer, Martina Crysandt, Ulrich Kaiser, Jan Moritz Middeke, Johannes Schetelig, Friedrich Stölzel, Hubert Serve, Claudia D Baldus, Uwe Platzbecker, Carsten Müller-Tidow, Martin Bornhäuser

TREATMENT OF AML WITH T(8;21) AND KIT MUTATIONS OR FLT3-ITD USING CHEMOTHERAPY PLUS MIDOSTAURIN: RESULTS OF THE MIDOKIT TRIAL
Christoph Röllig, Alwin Krämer, Christian Brandts, Björn Steffen, Kerstin Schäfer-Eckart, Stefan W Krause, Mathias Hänel, Albrecht Reichle, Sebastian Scholl, Andreas Neubauer, Michael Kramer, Jan-Henrik Mikesch, Johannes Schetelig, Annett Haake, Uwe Platzbecker, Hubert Serve, Claudia D Baldus, Carsten Müller-Tidow, Martin Bornhäuser, Gerhard Ehninger, Christian Thiede

STANDARDIZED IDENTIFICATION OF MEASURABLE RESIDUAL DISEASE (MRD) BY MULTICOLOR FLOW CYTOMETRY (MFC) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
Maximilian Röhnert, Malte von Bonin, Michael Kramer, Philipp Ensel, Nadja Holtschke, Christoph Röllig, Veit Bücklein, Marion Subklewe, Stefan Krause, Simon Völkl, Tobias Berg, Michael Rieger, Cornelia Brendel, Jörg Hoffmann, Nicole Hofmeister-Mielke, Richard Schlenk, Sylvie Freeman, Uta Oelschlägel

ROLE OF FUNCTIONAL PARAMETERS IN ELDERLY AML PATIENTS DEEMED UNFIT FOR INDUCTION CHEMOTHERAPY: RESULTS FROM THE DECIDER TRIAL
Valerie Hupfer, Claudia Schmoor, Richard F. Schlenk, Helmut R. Salih, Martina Crysandt, Michael Heuser, Hans-Walter Lindemann, Carsten Müller-Tidow, Gesine Bug, Ulrich Germing, Katharina S. Götze, Carsten Schwänen, Sebastian Scholl, Aristoteles Giagounidis, Andreas Neubauer, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Björn Hackanson, Gabriele Ihorst, Michael Lübbert

SIGNIFICANT EFFECT OF GEMTUZUMAB OZOGAMICIN ON MEASURABLE RESIDUAL DISEASE AND RISK OF RELAPSE IN PATIENTS WITH NEWLY DIAGNOSED NPM1 MUTATED AML- RESULTS FROM THE AMLSG 09-09 TRIAL
Silke Kapp-Schwoerer, Daniela Weber, Andrea Corbacioglu, Verena I. Gaidzik, Peter Paschka, Jan Krönke, Frauke Theis, Frank G. Rücker, Maria-Veronica Teleanu, Ekaterina Panina, Nikolaus Jahn, Julia K. Herzig, Lena Kubanek, Anika Schrade, Gudrun Göhring, Walter Fiedler, Thomas Kindler, Thomas Schroeder, Karin Tina Mayer, Michael Lübbert, Mohammed Wattad, Katharina S. Götze, Heinz A. Horst, Elisabeth Koller, Gerald Wulf, Jan Schleicher, Martin Bentz, Jürgen Krauter, Lars Bullinger, Julia Krzykalla, Axel Benner, Richard F. Schlenk, Felicitas Thol, Michael Heuser, Arnold Ganser, Hartmut Döhner, Konstanze Döhner

ACUTE MYELOID LEUKEMIA CELLS RESIST CHEMOTHERAPY THROUGH A TRANSIENT SENESCENCE-LIKE STATE
Cihangir Duy, Meng Li, Matt Teater, Cem Meydan, Francine Garrett-Bakelman, Christopher Chin, Hartmut Döhner, Richard D'Andrea, Christopher Mason, Martin Carroll, Ari Melnick

NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE (MRD) MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION (FLT3-ITD+ AML) TREATED WITH ADDITIONAL MIDOSTAURIN
Julia K. Herzig, Frank G. Rücker, Laura K. Schmalbrock, Tamara J. Blätte, Daniela Weber, Silke Kapp-Schwoerer, Andrea Corbacioglu, Verena I. Gaidzik, Peter Paschka, Ekaterina Panina, Nikolaus Jahn, Anika Schrade, Frauke Theis, Sabrina Skambraks, Walter Fiedler, Helmut R. Salih, Gerald Wulf, Hans Salwender, Thomas Schroeder, Katharina S. Götze, Thomas Kindler, Michael Lübbert, Richard F. Schlenk, Felicitas Thol, Michael Heuser, Arnold Ganser, Hartmut Döhner, Lars Bullinger, Konstanze Döhner

INTER-LABORATORY COMPARABILITY OF QUANTITATIVE ASSESSMENT OF MUTANT NPM1: RESULTS OF THE FIRST INTERNATIONAL ROUND-ROBIN TEST PERFORMED BY THE EUROPEAN LEUKEMIA NET (ELN) MRD WORKING PARTY (WP)
Christian Thiede, Robert Baker, Laura Dillon, Richard Dillon, Nicolas Duployez, Angela Hamblin, Duane Hassane, Michael Heuser, Sabine Jeromin, Marta Libura, Friedel Nollet, Yishai Ofran, Elisabeth Opplinger Leibundgut, Heike Pfeifer, Mikel Valganon, Peter Valk, Maria Teresa Voso, Konstanze Döhner

IVOSIDENIB IMPROVES OVERALL SURVIVAL RELATIVE TO STANDARD THERAPIES IN RELAPSED OR REFRACTORY MUTANT IDH1 AML: RESULTS FROM MATCHED COMPARISONS TO HISTORICAL CONTROLS
Peter Paschka, Hervé Dombret, Xavier Thomas, Christian Recher, Sylvain Chantepie, Pau Montesinos, Evelyn Acuña-Cruz, Paresh Vyas, Karl-Anton Kreuzer, Michael Heuser, Klaus H Metzeler, Michael Dennis, Bruno Quesnel, Mathilde Hunault-Berger, Mohamad Mohty, Arnaud Pigneux, Stéphane de Botton, Daniela Weber, Konstanze Döhner, Gary Milkovich, John Reitan, Sarah C MacDonald, Deborah Casso, Michael Storm, Hua Liu, Stephanie M Kapsalis, Eyal C Attar, Thomas Winkler, Hartmut Döhner

CC-486 MAINTENANCE THERAPY IS SAFE AND WELL TOLERATED IN PATIENTS AGED ≥75 YEARS WITH ACUTE MYELOID LEUKEMIA (AML) IN FIRST REMISSION FOLLOWING INDUCTION CHEMOTHERAPY: RESULTS FROM QUAZAR AML-001
Farhad Ravandi, Andrew Wei, Hartmut Döhner, Hervé Dombret, Gert Ossenkoppele, Michael Pfeilstöcker, Felicitas Thol, Georg Feldmann, Maria Teresa Voso, Paula Marlton, Michael Harvey, Valeria Santini, Luana Fianchi, Anna Candoni, Ignazia La Torre, Barry Skikne, Keshava Kumar, Qian Dong, CL Beach, Gail Roboz

ESCALATED DOSING SCHEDULES OF CC-486 ARE EFFECTIVE AND WELL TOLERATED FOR PATIENTS EXPERIENCING FIRST ACUTE MYELOID LEUKEMIA (AML) RELAPSE: RESULTS FROM THE PHASE III QUAZAR AML-001 MAINTENANCE TRIAL
Hartmut Döhner, Andrew Wei, Pau Montesinos, Hervé Dombret, Farhad Ravandi, Hamid Sayar, Kimmo Porkka, Irwindeep Sandhu, Francesco Passamonti, Fabrizio Pane, Tadeusz Robak, Jose Falantes, Andre Schuh, Gert Ossenkoppele, Ignazia La Torre, Barry Skikne, Keshava Kumar, Qian Dong, CL Beach, Gail Roboz

TP53 STATUS AND OUTCOME IN MYELODYSPLASTIC SYNDROMES WITH COMPLEX ABERRANT KARYOTYPES
Christina Ganster, Roxana Schaab, Katayoon Shirneshan, Lea Naomi Eder, Anna Mies, Ulrich Germing, Ahmet Elmaagacli, Francesc Solé, Laura Palomo, Jennifer Kaivers, Ulrike Söling, Frank Lange, Nicolaus Kroeger, Bernd Hertenstein, Konstanze Döhner, Gesine Bug, Barbara Hildebrandt, Marc Talló Parra, Maike Nickelsen, Bertram Glass, Uwe Platzbecker, Ulrike Bacher, Friederike Braulke, Julie Schanz, Detlef Haase

NOVEL INSIGHTS INTO GENOMIC CLASSIFICATION AND PROGNOSIS IN ACUTE MYELOID LEUKEMIA BASED ON A PAN-EUROPEAN PUBLIC-PRIVATE PARTNERSHIP, THE HARMONY ALLIANCE
Lars Bullinger, Javier Martinez Elicegui, Eric Sträng, Gastone Castellani, Caroline Heckman, Ana Heredia Casanoves, Jurjen Versluis, Moritz Gerstung, María Abáigar, Daniele Dall'Olio, Tommaso Matteuzzi, Laura Jamilis, Raúl Azibeiro Melchor, Peter JM Valk, Klaus Metzeler, Rosa Ayala, Joaquin Martinez Lopez, Hervé Dombret, Pau Montesinos, Jorge Sierra, Claude Preudomme, Frederik Damm, Ken Mills, Jiri Mayer, Christian Thiede, Maria Teresa Voso, Sergio Amadori, Guillermo Sanz, Frederico Calado, Konstance Döhner, Verena I Gaidzik, Michael Heuser, Pamela Bacon, Rubén Villoria Medina, Michel Van Speybroeck, Renate Schulze-Rath, Jesús María Hernández Rivas, Brian Huntly, Hartmut Döhner, Gert Ossenkoppele

ALL-TRANS RETINOIC ACID IMPROVES SURVIVAL IN ELDERLY AML PATIENTS BY DELAYING DECITABINE RESISTANCE DEVELOPMENT: RESULTS OF A RANDOMIZED TRIAL (DECIDER STUDY)
Michael Lübbert, Olga Grishina, Claudia Schmoor, Richard Schlenk, Edgar Jost, Martina Crysandt, Michael Heuser, Felicitas Thol, Helmut R. Salih, Marcus Schittenhelm, Ulrich Germing, Andrea Kuendgen, Katharina Götze, Hans-Walter Lindemann, Carsten Müller-Tidow, Gerhard Heil, Sebastian Scholl, Gesine Bug, Carsten Schwaenen, Aristoteles Giagounidis, Andreas Neubauer, Jürgen Krauter, Wolfram Brugger, Maike de Wit, Ralph Waesch, Heiko Becker, Annette May, Justus Duyster, Konstanze Döhner, Arnold Ganser, Björn Hackanson, Hartmut Döhner

ENASIDENIB PLUS AZACITIDINE SIGNIFICANTLY IMPROVES COMPLETE REMISSION AND OVERALL RESPONSE RATES VERSUS AZACITIDINE MONOTHERAPY IN MUTANT-IDH2 NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (ND-AML)
Courtney DiNardo, Andre Schuh, Eytan Stein, Pau Montesinos, Andrew Wei, Stéphane de Botton, Amer Zeidan, Amir Fathi, Lynn Quek, Hagop Kantarjian, Mark Frattini, Frederik Lersch, Jing Gong, Aleksandra Franovic, Paresh Vyas, Hartmut Döhner

COMPARATIVE RESULTS OF AZACITIDINE AND DECITABINE FROM A LARGE PROSPECTIVE PHASE 3 STUDY IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN-AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
Amer M. Zeidan, Pierre Fenaux, Marco Gobbi, Jiří Mayer, Gail J. Roboz, Jürgen Krauter, Tadeusz Robak, Hagop M. Kantarjian, Jan Novák, W.W. Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph Brandwein, Liana Gercheva, Judit Demeter, Elizabeth A. Griffiths, Karen W.L. Yee, Jean-Pierre Issa, Yong Hao, Mohammad Azab, Hartmut Döhner

MOLECULAR LANDSCAPE AND PROGNOSTIC IMPACT OF FLT3 INTERNAL TANDEM DUPLICATION INSERTION SITE IN ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE RATIFY STUDY (ALLIANCE 10603)
Frank G. Rücker, Ling Du, Tamara J. Blätte, Axel Benner, Julia Krzykalla, Insa Gathmann, Richard A. Larson, Maria Teresa Voso, Sergio Amadori, Thomas W. Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Michelle Geddes, Jorge Sierra, Celine Pallaud, Miguel Sanz, Theo de Witte, Dietger Niederwieser, Thomas Fischer, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Lars Bullinger, Clara D. Bloomfield, Richard M. Stone, Hartmut Döhner, Christian Thiede, Konstanze Döhner

HEALTH-RELATED QUALITY OF LIFE WITH CC-486 IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN FIRST REMISSION FOLLOWING INDUCTION CHEMOTHERAPY (IC): RESULTS FROM THE PHASE III QUAZAR AML-001 TRIAL
Gail Roboz, Hartmut Döhner, Christopher Pocock, Hervé Dombret, Farhad Ravandi, Jun Ho Jang, Dominik Selleslag, Jiří Mayer, Uwe Martens, Jane Liesveld, Teresa Bernal, Ming Chung Wang, Ignazia La Torre, Barry Skikne, Keshava Kumar, Qian Dong, Julia Braverman, Salem Abi Nehme, CL Beach, Andrew Wei

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VENETOCLAX WITH AZACITIDINE VS AZACITIDINE IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE THERAPY-VIALE-A
Courtney DiNardo, Brian Jonas, Vinod Pullarkat, Michael Thirman, Jacqueline Garcia, Andrew Wei, Hartmut Döhner, Pierre Fenaux, Christian Recher, Marina Konopleva, Walter Fiedler, Elisabeth Koller, Violaine Havelange, Andre Schuh, Jordi Esteve, Jianxiang Wang, Radovan Vrhovac, Roman Hajek, Kimmo Porkka, Arpad Illes, Ofir Wolach, Attilio Olivieri, Kazuhito Yamamoto, Jun-Ho Jang, Gunnar Juliusson, Vladimir Vorobyev, Su-Peng Yeh, Muhit Ozcan, Wan-Jen Hong, Ying Zhou, Jalaja Potluri, Keith Pratz


CML

MODEL-BASED INFERENCE AND CLASSIFICATION OF IMMUNOLOGICAL CONTROL MECHANISMS FROM TKI CESSATION AND DOSE REDUCTION IN CML PATIENTS
Ingmar Glauche, Tom Hähnel, Christoph Baldow, Andrea Gottschalk, Joëlle Guilhot, François Guilhot, Susanne Saussele, Satu Mustjoki, Stefanie Jilg, Philipp J. Jost, Stephanie Dulucq, François-Xavier Mahon, Silvia Cicconi, Richard E. Clark, Artur C. Fassoni, Ingo Roeder


MDS

ALL-TRANS RETINOIC ACID IMPROVES SURVIVAL IN ELDERLY AML PATIENTS BY DELAYING DECITABINE RESISTANCE DEVELOPMENT: RESULTS OF A RANDOMIZED TRIAL (DECIDER STUDY)
Michael Lübbert, Olga Grishina, Claudia Schmoor, Richard Schlenk, Edgar Jost, Martina Crysandt, Michael Heuser, Felicitas Thol, Helmut R. Salih, Marcus Schittenhelm, Ulrich Germing, Andrea Kuendgen, Katharina Götze, Hans-Walter Lindemann, Carsten Müller-Tidow, Gerhard Heil, Sebastian Scholl, Gesine Bug, Carsten Schwaenen, Aristoteles Giagounidis, Andreas Neubauer, Jürgen Krauter, Wolfram Brugger, Maike de Wit, Ralph Waesch, Heiko Becker, Annette May, Justus Duyster, Konstanze Döhner, Arnold Ganser, Björn Hackanson, Hartmut Döhner

ASSESSMENT OF DOSE-DEPENDENT RESPONSE TO LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) WITH RING SIDEROBLASTS IN THE PHASE 3 MEDALIST TRIAL
Uwe Platzbecker, Pierre Fenaux, Ghulam J. Mufti, Guillermo Garcia-Manero, Rami S. Komrokji, Rena Buckstein, María Diez-Campelo, Carlo Finelli, Mikkael A. Sekeres, Dominik Selleslag, Amy E. DeZern, Bruno Quesnel, Odile Beyne-Rauzy, Maria Teresa Voso, Peter L. Greenberg, Amer M. Zeidan, Lionel Adès, Amit Verma, Michael R. Savona, Abderrahmane Laadem, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Jessica Morison, Chrystal Louis, Peter G. Linde, Valeria Santini

TP53 STATUS AND OUTCOME IN MYELODYSPLASTIC SYNDROMES WITH COMPLEX ABERRANT KARYOTYPES
Christina Ganster, Roxana Schaab, Katayoon Shirneshan, Lea Naomi Eder, Anna Mies, Ulrich Germing, Ahmet Elmaagacli, Francesc Solé, Laura Palomo, Jennifer Kaivers, Ulrike Söling, Frank Lange, Nicolaus Kroeger, Bernd Hertenstein, Konstanze Döhner, Gesine Bug, Barbara Hildebrandt, Marc Talló Parra, Maike Nickelsen, Bertram Glass, Uwe Platzbecker, Ulrike Bacher, Friederike Braulke, Julie Schanz, Detlef Haase

SEQUENCE VARIANTS OF PPM1D IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITH AND WITHOUT COMPLEX ABERRATIONS
Lea Naomi Eder, Christina Ganster, Katayoon Shirneshan, Katharina Rittscher, Paolo Mazzeo, Roxana Schaab, Maria Kamper, Elzbieta Barbara Brzuszkiewicz, Roman Martin, Sascha Dierks, Detlef Haase


MPN

CLINICIAL, MORPHOLOGICAL AND GENETIC EVIDENCE FOR TWO INDEPENDENT DISEASES IN PATIENTS CONCURRENTLY POSITIVE FOR JAK2 V617F AND KIT D816V
Juliana Schwaab, Nicole Naumann, Johannes Luebke, Claire Oni, Mohamad Jawhar, Alice Fabarius, Georgia Metzgeroth, Lukas Reiter, Alicia Schmid, Karl Sotlar, Hans-Peter Horny, Claire Harrison, Wolf-Karsten Hofmann, Deepti Radia, Nicholas Cross, Andreas Reiter

THE WHO SUBCATEGORY 'MYELOID/LYMPHOID NEOPLASMS WITH EOSINOPHILIA AND REARRANGEMENT OF PDGFRA, PDGFRB OR FGFR1, OR PCM1-JAK2' REVISITED IN 74 PATIENTS: LACK OF EOSINOPHILIA AND PRESENCE OF MONOCYTOSIS
Georgia Metzgeroth, Laurenz Steiner, Juliana Schwaab, Nicole Naumann, Mohamad Jawhar, Sebastian Kreil, Torsten Haferlach, Alice Fabarius, Wolf-Karsten Hofmann, Nicholas C. P. Cross, Andreas Reiter

TRIPLE-NEGATIVE ESSENTIAL THROMBOCYTHEMIA: NOT PER SE LOW RISK. A CASE SERIES OF 22 PATIENTS
Parvis Sadjadian, Kai Wille, Tatjana Becker, Judith Pirngruber, Markus Tiemann, Martin Griesshammer

KIDNEY DYSFUNCTION IS ASSOCIATED WITH INCREASED THROMBOSIS BUT NOT SEVERE BLEEDING EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: AN ANALYSIS FROM THE GERMAN GSG-MPN BIOREGISTRY
Judith Gecht, Ioannis Tsoukakis, Kim Kricheldorf, Frank Stegelmann, Martine Klausmann, Martin Griesshammer, Holger Schulz, Wiebke Hollburg, Joachim R. Göthert, Katja Sockel, Florian H. Heidel, Norbert Gattermann, Christoph Maintz, Haifa K. Al-Ali, Uwe Platzbecker, Richard Hansen, Mathias Hänel, Stefani Parmentier, Martin Bommer, Heike L. Pahl, Fabian Lang, Susanne Isfort, Tim H. Brümmendorf, Konstanze Döhner, Steffen Koschmieder

KRT‑232, A FIRST‑IN‑CLASS, MURINE DOUBLE MINUTE 2 INHIBITOR (MDM2I), FOR MYELOFIBROSIS (MF) RELAPSED OR REFRACTORY (R/R) TO JANUS‑ASSOCIATED KINASE INHIBITOR (JAKI) TREATMENT (TX)
Haifa Kathrin Al-Ali, Regina García Delgado, Andrzej Lange, Andrzej Pluta, Donal P. McLornan, Pankit Vachhani, Gandhi Laurent Damaj, Philipp J. Jost, László Rejtő, Marek Hus, Sebastian Grosicki, Juan Carlos Hernández-Boluda, Joanne Ewing, Jesse McGreivy, Wayne P. Rothbaum, Hope Qamoos, Jean-Jacques Kiladjian, Srdan Verstovsek